Redeye gives its initial take on Xvivo’s Q3 report.
* Adj. EBITA -6% vs ABGSC, -5% vs ModFin consensus * Org.
Atria reported Q3 adjusted EBIT of EUR 25.4m, 7% above LSEG Data & Analytics consensus.
Redeye provides its key takeaways from Cheffelo’s CMD and updates its estimates and valuation follow...
Relais' Q3 adjusted EBITA came in slightly below LSEG Data & Analytics consensus.
We raise adjusted EBITA by 1% for 2026E-27E, following the impressive 80bp y/y margin uplift in Supp...
Redeye was hoping for a bit more in terms of topline, but market demand has been hesitant, particula...
* Return to growth in Q3 driven by both M&A and organic recovery * Enedo headwinds should be more th...
* '25e-'27e adj. EBITA up 12-5% * Encouraging efficiency improvements and strategic initiatives * Tr...
Lumito är ett medicinteknikbolag som utvecklar och säljer en patenterad teknik för mer precisa och o...
Active Biotechs styrelse har beslutat om nyemission av aktier för minst 70 mkr.
Flexion has entered into a partnership with Xsolla, a global U.
Consti reports its Q3 results on October 24th. We expect the improved backlog to support continued g...
Relais Q3 adjusted EBITA of EUR 10.9m was up 19% y/y and came 5% below LSEG Data & Analytics consens...
* 2% sales beat & adj. EBIT SEK 45m vs. ABGSCe 29m * Announces restructuring programme of SEK 20m p.
Redeye provides its initial take on Relais’ Q3 2025 report, which featured an adjusted EBITA that al...
Redeye updates on EG7 ahead of Q3-results (due November 11) where we expect stable quarter with simi...
Redeye has updated its estimates following Physitrack’s Q3 2025 report, which was broadly in line wi...
Redeye updates its Base Case and forecasts for Lime following the Q3 report.
Redeye updates its estimates and valuation after Indutrade’s Q3 2025 report.
